A retrospective, 12-month, multicenter study to evaluate real-world brolucizumab effectiveness and safety in Japanese patients with neovascular age-related macular degeneration (nAMD)

A retrospective, 12-month, multicenter study to evaluate real-world brolucizumab effectiveness and safety in Japanese patients with neovascular age-related macular degeneration (nAMD) - Pheasant Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1050210159

Enrollment

500

Registered

2022-01-22

Start date

2022-04-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neovascular Age-related Macular Degeneration

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Diagnosis of nAMD 2.Patients with >= 50 years of age at index 3.Receipt of first injection of brolucizumab during the index period 4.Signed or Verbal informed consent

Exclusion criteria

Exclusion criteria: 1. Patients treated for RVO, DME, mCNV, and have diagnoses of diabetes-related macular degeneration within 6 months prior to the index date 2. Any active intraocular or periocular infection or active intraocular inflammation in the study eye at index date 3.Patients who have any contraindication and are not eligible for treatment with brolucizumab as according to the label 4. Patients who were treated with more than 3 types of anti-VEGF before index date (5th line brolucizumab patients or more) 5. Patients participating in parallel in an interventional clinical trial Note: if a patient experiences an adverse event, they may still be recruited in another study following this adverse event if they fulfill their inclusion criteria. Their data will still be collected as planned by the current protocol 6. Patients participating in Post-Marketing surveillance with brolucizumab

Design outcomes

Primary

Measure	Time frame
Percentage(%) of patients that are absent of SRF and IRF at Month 12. The endpoint formulated in estimand terms is : -Population : real-world nAMD patients -Treatment : brolucizumab as received in routine care -Variable(Endpoint / Outcome) : composite binary: absence of IRF and the absence of SRF. -Summary measure for the variable : percentage of treated patients who reach the endpoint at 12 months -Intercurrent events treatment discontinuation for any reason (including switching to another anti-VEGF) -Strategy how to deal with intercurrent events : while-on-treatment strategy. Patients who have discontinued brolucizumab before Month 12 will be counted as not having achieved the endpoint of fluid resolution (absence of SRF and IRF), unless they reached it at the last visit while still on brolucizumab treatment before the discontinuation.	—

Measure

Time frame

Percentage(%) of patients that are absent of SRF and IRF at Month 12. The endpoint formulated in estimand terms is : -Population : real-world nAMD patients -Treatment : brolucizumab as received in routine care -Variable(Endpoint / Outcome) : composite binary: absence of IRF and the absence of SRF. -Summary measure for the variable : percentage of treated patients who reach the endpoint at 12 months -Intercurrent events treatment discontinuation for any reason (including switching to another anti-VEGF) -Strategy how to deal with intercurrent events : while-on-treatment strategy. Patients who have discontinued brolucizumab before Month 12 will be counted as not having achieved the endpoint of fluid resolution (absence of SRF and IRF), unless they reached it at the last visit while still on brolucizumab treatment before the discontinuation.

—

Contacts

Public ContactDirect Novartis

Novartis Pharma. K.K.

phj_medical.me_cr@novartis.com+81-120-003-293

Outcome results